Navigation Links
Xenon Licenses Antisense Drug XEN701 From Isis and Initiates Preclinical Toxicology Studies
Date:6/10/2013

CARLSBAD, Calif. and VANCOUVER, British Columbia, June 10, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and Xenon Pharmaceuticals Inc. announced today that Xenon has exercised its option  to an exclusive worldwide license to XEN701, an antisense drug discovered in a collaboration between Isis and Xenon.  For the license of XEN701, Isis earns a $2 million payment from Xenon.  XEN701 is a drug candidate designed to inhibit the production of hepcidin, a target Xenon identified utilizing its extreme genetics platform for the treatment of anemia of chronic disorders (ACD).  XEN701 is currently being evaluated in studies to support clinical development.  Xenon plans to initially develop XEN701 for patients with chronic kidney disease who are intolerant of or who are poor responders to erythropoietin (Epo) therapy. XEN701 is the first drug to enter development from Isis' collaboration with Xenon.

"We are delighted with the advances we have made with Isis to discover XEN701," said Simon Pimstone, Xenon's President and CEO. "XEN701 has the potential to provide significant therapeutic benefit to patients with ACD through a novel non-Epo receptor based mechanism and we are looking forward to initiating clinic studies with this compound."

"We are pleased with the success of our collaboration with Xenon and the opportunity to apply our antisense drug discovery technology to discover XEN701, a novel antisense drug to treat ACD," said B. Lynne Parshall, chief operating officer at Isis.  "A key component of our business strategy is to exploit the broad applicability of our antisense technology platform in order to develop antisense drugs in many different therapeutic areas.  By working with partners like Xenon, who are highly innovative and dedicated to a therapeutic area, we are able to expand the breadth of our antisense drug pipeline while staying focused on our internal drug discovery and development activities."

In 2010, Isis entered into collaboration with Xenon to discover and develop antisense drugs as novel treatments for ACD.  Under the terms of the agreement, Isis received an undisclosed upfront payment in the form of a convertible promissory note from Xenon to discover and develop antisense drugs to the targets hepcidin and hemojuvelin.  Upon the identification of a development candidate, Xenon has the option to exclusively license the development and worldwide commercialization rights for these antisense drugs from Isis.  Xenon paid Isis a $2 million fee to exercise its option to license XEN701. Xenon is responsible for all future development and commercialization of XEN701 and Isis is eligible to receive development and commercial milestone payments and royalties from Xenon on sales of XEN701, as well as a portion of sublicense revenue. 

About ACD
ACD is the second most common form of anemia worldwide and commonly acquired disorder that is associated with a variety of conditions including kidney disease, malignancy and other clinical settings of chronic inflammation such as inflammatory bowel disease. Utilizing its genetics platform, Xenon's discovery of the genes underlying the rare genetic disorder juvenile hemochromatosis (JH) led to its selection of hepcidin, a protein produced in the liver, as a drug target to treat patients with ACD. JH, where hepcidin is genetically deficient, is a disorder of iron metabolism where white blood cells are iron-depleted and intestinal iron absorption is enhanced, resulting in total body iron overload. ACD, on the other hand, is characterized by iron-rich white blood cells and impaired intestinal iron absorption due to elevated hepcidin, which can result in restricted iron availability for red blood cell production and anemia. Inhibition of hepcidin with XEN701 is predicted to improve the anemia by reversing these iron disturbances facilitating new red blood cell production. 

ABOUT XENON PHARMACEUTICALS INC.
Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing novel therapies for rare diseases. For more information, visit the Company's website at www.xenon-pharma.com.  

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Genzyme is also pursuing marketing approval of KYNAMRO in other markets.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding Isis' strategic alliance with Xenon, and the discovery, development, activity, therapeutic and commercial potential and safety of Isis' antisense drugs, including XEN701, for the treatment of anemia of chronic disorders.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.

XENON PHARMACEUTICALS' FORWARD-LOOKING STATEMENT 
This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Xenon Announces Appointment of EVP, Research & Development
2. Xenon Named Life Sciences Company of the Year by LifeSciences British Columbia
3. Xenon Exclusively Licenses to Merck Compounds for a Novel Target for Cardiovascular Disease
4. MetaStat, Inc. Executes Two New Licenses
5. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
6. Ventana licenses Gen-Probe IP for measuring ERG protein in prostate cancer patients
7. NTT DATA Licenses DATATRAK ONE™ for China
8. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
9. West Health Institute licenses Kinect-based physical therapy technology to Reflexion Health; West Health Investment Fund makes $4.25 million investment
10. Parios Regenerative Sciences, Inc. Licenses Exclusive Rights to Organic Nanotechnology for Skin Repair
11. uniQure Licenses RNA Interference Technology to Advance Huntingtons Disease Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... Mostyn Law and Gulf Coast Regional Blood Center to host ... Mostyn Law family has had 3 members that needed ... Mostyn Law is partnering with Gulf Coast Regional Blood Center ... Blood supplies are running low. Gulf Coast Regional Blood Center,s ... August. That is why the blood center reached out to ...
(Date:8/15/2017)... Calif. , Aug. 15, 2017  AOTI Inc. announced today ... Oxygen Therapy Inc., has recently opened a New York City Office ... ever-increasing usage of its unique Topical Wound Oxygen (TWO 2 ) ... by the Accreditation Commission for Health Care (ACHC) under the company,s ... ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
Breaking Medicine Technology:
(Date:8/23/2017)... ... August 23, 2017 , ... A new ... Orthopaedic Surgeons , points out that therapeutic modalities (physical therapy) is an important ... to the report, a wider scope of physical therapy options is showing promising ...
(Date:8/22/2017)... ... August 22, 2017 , ... The old adage ... as simple as eating healthy foods. But this well-known piece of nutrition advice ... or breaking apart carbohydrates—depends not only on properties of the food but also ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... solutions, announced recently the availability of a new professional fee E/M leveling calculator ... their service to the healthcare industry. E/M coding is complex which supports the ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Wilderness Voices”: a collection ... travel. “Wilderness Voices” is the creation of published author, Martha McKown, an ordained ... was inspired as a very young child when her older sisters studied High School ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... the Founder and Managing Member for t4 Leadership Development & Consulting. He has ... his definition of “success”: physician leadership development, servant leadership, data driven process improvement, ...
Breaking Medicine News(10 mins):